spacer
home > epc > winter 2018 > ticking boxes
PUBLICATIONS
European Pharmaceutical Contractor

Ticking Boxes

With the advent of novel immuno-therapeutic approaches to cancer, the world has entered a new stage of medicine. Rather than targeting cancer cells directly with traditional tools like chemotherapy or radiation, immunotherapy seeks ways to use the bodyís own immune system to eradicate or inhibit the growth of cancers.

The field of immuno-oncology (IO) focuses on determining how to activate pre-existing immune cells to attack cancerous targets. Monoclonal antibody therapies have shown to be successful in many indications and continue to be an effective and viable approach to treating cancer. According to Beth Kiernan, pharmaceutical research analyst at Thomson Reuters, therapeutic cancer vaccines currently comprise 14% of IO clinical trials (1). Although many vaccine trials are in early stages, advancement has been made into later stages, showing potential for desirable outcomes using this strategy.

Perhaps the most groundbreaking and rapidly expanding modality of IO is the development of the utilisation of checkpoint inhibitors. Though the industry is just scratching the surface of its promise, checkpoint inhibitors have profound implications on the future of oncological therapies, revolutionising the research industry. Checkpoint inhibitor therapies are able to span across cancer types and stages, providing hope even in the most despairing of circumstances.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Elizabeth Koury is Vice President of Scientific Affairs at LabConnect. She is responsible for leading a team of scientists, sample management professionals, and contract managers strategically supporting clients within the pharma industry. Elizabeth earned a bachelorís in biology/allied health from Elizabethtown College, US, and a masterís in pharmaceutical chemistry from Lehigh University, US. She has more than 20 years of experience in conducting and overseeing scientific research in the areas of neuroscience, oncology, and immunology.

Jeff Mayhew is Chief Development Officer at LabConnect. As one of the founding partners in 2002, he has three decades of operations and business development experience within the healthcare industry. Before starting LabConnect, Jeff was founder and Director of Nexus Health Management International, where he was involved in the development of inpatient behavioural health services in Southeast Asia. Prior to that, he served as Vice President of Strategic Alliance Development for Charter Behavioural Health Systems, among other key leadership positions.
spacer
Elizabeth Koury
spacer
spacer
spacer
Jeff Mayhew
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

NDA Group Releases Data Comparing FDA and EMA Ahead of Annual DIA Europe in Basel

Today NDA Group announced their findings from its fifth annual comparison of drug approvals in Europe and the United States, in preparation for this yearís DIA Europe in Basel, Switzerland. The figures highlight the continued differences between the two regions, and the need for a global approach to drug development to ensure success across both continents.
More info >>

White Papers

e-tools enhance clinical trial performance

e-novex

In todayís ever-evolving medical business, technological changes require innovation to meet growing market demands and to bring about advances in the industry. One such development currently taking place in the field of clinical research is how e-tools are initiating a boost in the productivity of clinical trials.
More info >>

 
Industry Events

RDD Asia 2018

14-15 November 2018, Grand Hyatt Kochi, Kerala, India

A must-attend meeting for pulmonary and nasal researchers, inhaled product developers and vendors active in this important pharmaceutical niche.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement